Skip to content

A retrospective study on the relationship between 18F-MISO hypoxia scanning parameters and the clinical outcomes of carbon ion radiotherapy for locally advanced non-small cell lung cancer

A retrospective study on the relationship between 18F-MISO hypoxia scanning parameters and the clinical outcomes of carbon ion radiotherapy for locally advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102877
Enrollment
Unknown
Registered
2025-05-21
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Sponsors

Shanghai Proton and Heavy Ion Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) written informed consent obtained, 2) age >= 18 years, 3) cytologically or histologically confirmed NSCLC, 4) stage IIB–IIIC (the American Joint Committee on Cancer staging 8th edition) with primary tumour and/or metastatic lymph nodes >= 3 cm in maximum diameter prior to CIRT, 5) a baseline 18F-FDG PET/CT imaging for staging, and 6) availability of both pre-and post-CIRT 18F-MISO PET/CT scans

Exclusion criteria

Exclusion criteria: 1) At the same time, there are uncontrolled malignant tumors that may significantly shorten the expected survival of lung cancer in the patient; 2) Patients with pacemakers, such as high-energy rays that may interfere with the normal function of the pacemaker; If there is a metal prosthesis implant in the body, it may significantly affect the calculation of the target radiation dose; 3) HIV-positive, including prior treatment on antiretroviral therapy; Chronic hepatitis B, viral replication phase; active phase of hepatitis C; active syphilis; 4) have a history of psychiatric illness that may impede the completion of treatment; 5) Have serious comorbidities that may affect the delivery of radiotherapy, including: a) uncontrolled acute inflammation; b) Uncontrolled unstable angina, congestive heart failure, myocardial infarction, cerebral hemorrhage, severe chronic obstructive pulmonary disease and other cardiopulmonary and cerebral diseases, which may lead to treatment risks as assessed by specialists; c) Pregnant or lactating; d) Other diseases that may affect particle therapy; 6) the department discussed that particle radiotherapy would not be able to provide patients with a clear benefit; 7) After repeated communication, they are still unable to understand the purpose of treatment, unable to cooperate with treatment, or unwilling to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Local control rate;

Secondary

MeasureTime frame
Progression-free survival rate;Overall survival rate;

Countries

China

Contacts

Public ContactChen Jian

Shanghai Proton and Heavy Ion Center

jian.chen@sphic.org.cn+86 21 3829 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026